Valneva: Austrian/French biotech company Valneva SE announced positive initial booster data and final Phase 1 data for its leading, unique Lyme disease vaccine candidate VLA15. To investigate whether a VLA15 booster will elicit an anamnestic response1, Valneva amended its Phase 1 study protocol during 2018, adding a booster dose in a sub-cohort of the Phase 1 study population. At the same time the full Phase 1 study population has been followed-up across all doses for up to one year, providing the final Phase 1 data.  Wolfgang Bender, Chief Medical Officer of Valneva, commented, “These encouraging results support our current development plans and hypothesis for our leading vaccine candidate, VLA15. As a result of these findings, we have included a VLA15 booster in the Phase 2 program that is now underway. Addressing the significant, and growing, unmet medical need caused by Lyme disease is our top priority, VLA15 remains the only Lyme vaccine candidate in clinical development worldwide.”
Valneva: weekly performance: -3.21%